Comparing Baxalta (NYSE:BXLT) & Syros Pharmaceuticals (SYRS)

Baxalta (NYSE: BXLT) and Syros Pharmaceuticals (NASDAQ:SYRS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

56.0% of Syros Pharmaceuticals shares are held by institutional investors. 33.6% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Dividends

Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Syros Pharmaceuticals does not pay a dividend. Baxalta pays out 23.5% of its earnings in the form of a dividend. Baxalta has increased its dividend for 2 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Baxalta and Syros Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxalta 0 0 0 0 N/A
Syros Pharmaceuticals 0 2 6 0 2.75

Syros Pharmaceuticals has a consensus target price of $23.83, indicating a potential upside of 151.68%. Given Syros Pharmaceuticals’ higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Baxalta.

Valuation and Earnings

This table compares Baxalta and Syros Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baxalta N/A N/A N/A $1.19 38.67
Syros Pharmaceuticals $320,000.00 905.86 -$47.74 million ($2.01) -4.71

Baxalta has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Baxalta, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Baxalta and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxalta 9.37% 14.28% 4.62%
Syros Pharmaceuticals N/A -62.01% -55.65%

Summary

Baxalta beats Syros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Baxalta Company Profile

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply